Dissolution Testing
Dissolution testing measures the rate and extent to which a drug substance releases from a solid oral dosage form into a defined medium, standing in as a practical, in-vitro proxy for a step that would otherwise only be observable inside the body. It is a specification test, a formulation-development tool, and — under a validated in-vitro/in-vivo correlation — sometimes a surrogate for a bioequivalence study, which is why its method development and control receive outsized regulatory attention relative to its apparent simplicity.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 19 LINKSDissolution is where a specification stops describing the product and starts describing the test: apparatus, medium and agitation are chosen, and a method that discriminates nothing will pass every batch including the bad ones.
06 · QUALITY MATURITY — DISSOLUTION TESTING, REACTIVE TO ADAPTIVE
The method came from a monograph or a predecessor product. Nobody has asked whether it can distinguish an acceptable unit from an unacceptable one.
The method is validated and the apparatus is calibrated, but discriminatory power was never demonstrated and the specification was set from the batches that happened to exist.
Discrimination is demonstrated against deliberately varied batches, the medium and apparatus choice is justified, and the specification derives from batches with known clinical or bioavailability standing.
Profiles are trended rather than only judged against the stage limits, so a formulation or equipment drift shows as a shape change before a batch fails.
The method is a development instrument as well as a release test: it informs formulation and process decisions, and any in-vitro to in-vivo relationship is stated with its evidence and its limits.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 2 regulatory bodies: ICH, USP.
RECORDS & OBJECTIVE EVIDENCE
- Method development data justifying apparatus, medium, volume and agitation
- Discriminatory power studies against deliberately varied batches
- Method validation covering the full profile, not only the release time point
- Apparatus qualification and periodic mechanical calibration records
- The specification justification, traced to batches with clinical or bioavailability standing
COMMON INSPECTION FINDINGS
- A method adopted from a monograph or a related product with no development rationale on file
- A specification set from manufacturing history rather than from clinically relevant batches
- Discriminatory power never demonstrated, so the test cannot fail a defective batch
- Apparatus mechanical qualification lapsed or performed without the vibration and alignment checks
- Repeat testing to a passing result without an investigation that reached a cause
What the Test Actually Measures
A dosage unit is placed in a vessel of dissolution medium held at a controlled temperature and agitation rate, and samples are withdrawn at defined time points to measure how much drug has dissolved. Compendial apparatus designs — commonly a rotating basket or a rotating paddle, with less common flow-through and reciprocating-cylinder designs for harder-to-test formulations — are standardized precisely because small differences in vessel geometry, agitation, or sampling technique can shift the result more than a genuine formulation difference would.
Method Development Under ICH Q14 and Q2(R2)
Choosing dissolution medium, agitation speed, and sampling times is method development in the fullest sense described by ICH Q14, and the resulting method is validated for accuracy, precision, specificity, and robustness under ICH Q2(R2) — the same framework used for any other analytical procedure, applied here to a physical-release test rather than a purely chemical assay.
Specification-Setting and the IVIVC Question
Dissolution specifications are set to be discriminating enough to detect a manufacturing or formulation change that would matter clinically, without being so tight that acceptable batch-to-batch variation fails routinely. Where a validated in-vitro/in-vivo correlation (IVIVC) has been established, dissolution results can sometimes support a biowaiver or justify a post-approval change without a new bioequivalence study — a link that only holds for the specific formulation and correlation it was built on.
Common Failure Modes
Recurring dissolution problems SPEQ sees are less often chemistry than physical execution: undegassed medium introducing air bubbles that shield tablet surfaces, vessel misalignment or off-center stirring shafts, sampling probe position drifting from the specified height, and filter interactions that adsorb drug substance and depress recovery. Because these are execution failures rather than product failures, a dissolution out-of-specification result deserves the same rigorous, evidence-based investigation as any other laboratory result before a batch is dispositioned.
FREQUENTLY ASKED
Why does dissolution apparatus alignment matter so much?
Small deviations in vessel centering, stirring-element wobble, or probe height change local hydrodynamics enough to shift the measured dissolution rate, independent of any real difference in the tested product — which is why apparatus qualification and performance verification are treated as critical, not routine housekeeping.
Can dissolution testing replace a bioequivalence study?
Only where a validated in-vitro/in-vivo correlation exists for that specific formulation, or under a defined biowaiver policy — dissolution alone is not automatically an accepted surrogate for every product.
Who validates a new dissolution method?
The sponsor or manufacturer developing the method, following the accuracy, precision, specificity, and robustness expectations in ICH Q2(R2), typically informed by the systematic development approach in ICH Q14.
What is the first step in investigating a dissolution OOS result?
A laboratory-execution review — checking for degassing, apparatus alignment, sampling technique, and filter or media issues — before any conclusion is drawn about the product itself, consistent with standard OOS investigation practice.